We are thrilled to share the exciting news that Ms. Jennifer Che, our President and Managing Director, has been once again recognized on the IAM Strategy 300: The World's Leading IP Strategists of the year for 2025.


The IAM Strategy 300 is a guide to the pioneers in the industry. It recognizes individuals who are “leading the way in developing and implementing strategies that maximize the value of IP portfolios.” Individuals are nominated by the community, and only those identified by market sources for their “exceptional skill sets and profound insights into patent matters” are featured in the IAM Strategy 300. Jennifer's inclusion on this list underscores her outstanding credentials and unique strengths.


With a robust 20-year career as a scientist, patent attorney, and executive, Jennifer has helped numerous companies, institutions, inventors, and start-ups devise effective global intellectual property (IP) strategies. She excels at crafting integrated IP solutions that involve technical, regulatory, and long-range business needs. Jennifer's extensive experience in the U.S. and Greater China gives her a distinctive strategic eye for navigating complex cross-border IP challenges.


Jennifer is a highly regarded speaker and regularly gives talks in Hong Kong, Mainland China, the US, and around the world. She is also the founder and a frequent author of the blog chinapatentstrategy.com.
Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

我们的过去活动

Recommended Insights

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

2019年11月21日
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents

2026年1月29日
Each year the CNIPA publishes its Top Ten Patent Re-examination and Invalidation Cases for the previous year. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Today we’ll be sharing about one of the Top 10 Invalidation Cases in 2024 involving Microsoft (China) Co., Ltd. […]

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

2023年11月10日
On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see […]
Top crossarrow-right